Neulasta Market, By Indication (Chemotherapy-Induced Febrile Neutropenia and Hematopoietic Subsyndrome of Acute Radiation Syndrome (ARS)), By Dosage Form (Prefilled Syringe and On-body Injector), By Age Group (Pediatric and Adult), By End User (Hospitals,

The Global Neulasta Market is estimated to be valued at USD 210.3 million in 2025 and is expected to reach USD 95.3 million by 2032, exhibiting a compound annual growth rate (CAGR) of -10.7% from 2025 to 2032. The Global Neulasta Market, a key segment within the biotechnology and pharmaceutical industry, is currently experiencing slow growth, with a negative CAGR. This market focuses on pegfilgrastim-based therapeutic solutions designed to address chemotherapy-induced neutropenia in cancer patients. Neulasta, developed as a long-acting granulocyte colony-stimulating factor (G-CSF), plays a significant role in stimulating neutrophil production, thereby reducing infection risk for patients undergoing myelosuppressive chemotherapy.

However, despite its critical role, the market is facing challenges. The increasing availability of biosimilars and other cost-effective alternatives is impacting market growth. The market is also influenced by factors such as the ongoing rise in cancer incidence, evolving healthcare systems, and growing awareness of supportive care in oncology. Though Neulasta remains a key treatment option, the introduction of newer and more affordable treatments is creating a shift in the market dynamics.

The therapeutic significance of Neulasta still extends beyond its primary indication, helping cancer patients maintain chemotherapy schedules without dose reductions or delays, which in turn, can improve treatment outcomes and quality of life. But with the rise of biosimilars and alternative therapies, pharmaceutical companies, healthcare providers, and investors must adapt to a more competitive landscape, where cost-effectiveness and patient-centric solutions are becoming more critical for survival and growth in the market.

Market Dynamics:

The global Neulasta market is currently experiencing slow growth and a negative CAGR, primarily driven by the increasing global cancer burden. While Neulasta remains crucial for preventing severe neutropenia in chemotherapy patients, the market faces significant challenges, including high treatment costs, limited access in developing regions, and rising competition from biosimilars. Technological advancements in drug delivery systems, such as on-body injectors and enhanced auto-injectors, have improved patient compliance, but these innovations have not been sufficient to overcome the market’s decline.

Regulatory complexities and stringent approval processes for new formulations and delivery mechanisms further slow market expansion, increasing development costs and delaying market entry. Despite these challenges, opportunities exist, especially in emerging economies with improving healthcare infrastructure and rising healthcare expenditures. However, the market’s overall growth remains constrained, and expanding beyond traditional chemotherapy-induced neutropenia to broader indications could offer potential revenue streams.

Key Features of the Study:

• This report provides in-depth analysis of the global Neulasta market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Neulasta market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key company covered as a part of this study include Amgen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Neulasta market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Neulasta market

Market Segmentation

• Indication Insights (Revenue, USD Mn, 2020 - 2032)
• Chemotherapy-Induced Febrile Neutropenia
• Hematopoietic Subsyndrome of Acute Radiation Syndrome (ARS)
• Dosage Form Insights (Revenue, USD Mn, 2020 - 2032)
• Prefilled Syringe
• On-body Injector
• Age Group Insights (Revenue, USD Mn, 2020 - 2032)
• Pediatric
• Adult
• End User Insights (Revenue, USD Mn, 2020 - 2032)
• Hospitals
• Specialty Pharmacies
• Cancer Treatment Centers
• Oncology Clinics & Infusion Centers
• Others (Research and Academic Institutes, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Amgen Inc.

Show more